Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights

Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis

(2014) M. A. Nowell et al.   JOURNAL OF IMMUNOLOGY

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes

(2013) Jung-Yoon Choe et al.   ARTHRITIS RESEARCH & THERAPY

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab

(2012) Emilio Besada et al.   CLINICAL RHEUMATOLOGY

The interleukin-6 pathway and atherosclerosis

(2012) S Matthijs Boekholdt et al.   LANCET

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012)   LANCET

The pathogenesis of rheumatoid arthritis: new insights from old clinical data?

(2012) Josef S. Smolen et al.   Nature Reviews Rheumatology

Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study

(2012) V. Strand et al.   RHEUMATOLOGY

Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis

(2012) K. Kayakabe et al.   RHEUMATOLOGY

A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis

(2011) A.D. Protogerou et al.   ATHEROSCLEROSIS

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

(2011) Masahiko Mihara et al.   CLINICAL SCIENCE

Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis

(2011) K. Henriksen et al.   ENDOCRINE REVIEWS

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990-2010: before and after introduction of biologic agents

(2011) E. Hallert et al.   RHEUMATOLOGY

Very early improvements in the wrist and hand assessed by power doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis

(2011) Kensuke Kume et al.   ARTHRITIS CARE & RESEARCH

Meeting report on protein particles and immunogenicity of therapeutic proteins: Filling in the gaps in risk evaluation and mitigation

(2010) John Carpenter et al.   BIOLOGICALS

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

(2010) S.-N. J. Song et al.   BLOOD

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Atherosclerosis in Rheumatoid Arthritis Versus Diabetes

(2009) Kimon S. Stamatelopoulos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

(2009) Patrick Garnero et al.   ARTHRITIS AND RHEUMATISM

Osteoclasts and Arthritis

(2009) Georg Schett et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Management of cardiovascular disease risk in chronic inflammatory disorders

(2009) Mariana J. Kaplan   Nature Reviews Rheumatology

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production

(2009) Misato Hashizume et al.   RHEUMATOLOGY INTERNATIONAL

IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system

(2009) Misato Hashizume et al.   RHEUMATOLOGY INTERNATIONAL

Evidence of Systemic Inflammation and Estimation of Coronary Artery Disease Risk: A Population Perspective

(2008) Peter W.F. Wilson   AMERICAN JOURNAL OF MEDICINE

Osteoclasts secrete non-bone derived signals that induce bone formation

(2008) Morten A. Karsdal et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, Ameliorates Joint Swelling in Established Monkey Collagen-Induced Arthritis

(2008) Yasushi Uchiyama et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Autoantibody production in patients treated with anti-TNF-α

(2008) Fabiola Atzeni et al.   Expert Review of Clinical Immunology

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-  and IL-17

(2008) M. Hashizume et al.   RHEUMATOLOGY

Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms

(2008) Larry W. Moreland et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

(2007) A Gonzalez et al.   ANNALS OF THE RHEUMATIC DISEASES

Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: Implications for fatigue

(2007) Mary C. Davis et al.   BRAIN BEHAVIOR AND IMMUNITY